Biokinetics of yttrium-90–labeled huBrE-3 monoclonal antibody
Article first published online: 12 FEB 2002
Copyright © 2002 American Cancer Society
Supplement: Eighth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer
Volume 94, Issue Supplement 4, pages 1240–1248, 15 February 2002
How to Cite
Johnson, T. K., Cole, W., Quaife, R. A., Lear, J. L., Ceriani, R. L., Jones, R. B. and Cagnoni, P. J. (2002), Biokinetics of yttrium-90–labeled huBrE-3 monoclonal antibody. Cancer, 94: 1240–1248. doi: 10.1002/cncr.10292
- Issue published online: 12 FEB 2002
- Article first published online: 12 FEB 2002
- Manuscript Accepted: 14 NOV 2001
- Manuscript Received: 31 OCT 2001
- NIH. Grant Numbers: ROI-CA62352, ROI-CA61532
- 4Phase I trial of IP admininstered 90Y labeled CYT-103 MoAb for refractory colorectal carcinomas [abstract]. J Nucl Med 1991; 32: 1052., , , , , , et al.
- 5Phase I trial of Yttrium-90-HuM195 (Anti-CD33) in myeloid leukemia: potential for myeloablation. Cancer Biother Radiopharm 2000;15:408., , , , , , , , and .